CCL2 and neoplasm: At the same time, serum levels of proinflammatory cytokines such as CCL2, IL‐6, and MIP‐1β were also significantly elevated, indicating an enhancement of the systemic anti‐tumor immune response after P5091@RMPs‐R4F treatment.